Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0248 | 0.0556 | 0.5 |
Schistosoma mansoni | memapsin-2 (A01 family) | 0.0492 | 0.2932 | 0.592 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0452 | 0.2543 | 0.2543 |
Loa Loa (eye worm) | hypothetical protein | 0.0261 | 0.0689 | 0.1392 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0438 | 0.2409 | 1 |
Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.1218 | 1 | 1 |
Schistosoma mansoni | furin-1 (S08 family) | 0.0296 | 0.1025 | 0.207 |
Loa Loa (eye worm) | endoprotease bli-4 | 0.0699 | 0.4952 | 1 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.0438 | 0.2409 | 0.2409 |
Echinococcus granulosus | furin | 0.0699 | 0.4952 | 0.4952 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0699 | 0.4952 | 1 |
Brugia malayi | endoprotease bli-4 precursor | 0.0699 | 0.4952 | 1 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0452 | 0.2543 | 0.2543 |
Echinococcus multilocularis | 0.0543 | 0.3434 | 0.3434 | |
Brugia malayi | celfurPC protein | 0.0543 | 0.3434 | 0.3699 |
Loa Loa (eye worm) | hypothetical protein | 0.0699 | 0.4952 | 1 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0438 | 0.2409 | 1 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.0438 | 0.2409 | 0.2409 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Survival (ADMET) | = 75.8 % | Intrinsic cytotoxicity against human K562 cells assessed as cell survival at 10 uM after 24 hrs by MTT assay | ChEMBL. | 25634041 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.